Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02366156 · ClinicalTrials.gov registry record · NA
A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism
A NA study, sponsored by Access Business Group.
- Completed
- Registry status
- NA
- Development phase
- 93
- Enrollment target
NCT02366156: Completed NA study, sponsored by Access Business Group.
NCT02366156 is a NA study that has completed, run by Access Business Group. The registered enrollment target is 93 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02366156, a NA study, has completed, sponsored by Access Business Group.
- COMPLETED
- Registry status
- NA
- Development phase
- 93 participants
- Enrollment target
Study Summary
This study will evaluate the effects of encapsulated botanical extracts, previously shown to inhibit the enzyme diacylglycerol-acyltransferase-1 (DGAT-1) in vitro, on fasting and postprandial lipid metabolism during an oral fat tolerance test (OFTT) in apparently healthy, overweight and obese adult men and women.
Primary Outcome
Change in fasting plasma TG
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Low Dose Grape Blend
- DIETARY_SUPPLEMENT High Dose Grape Blend
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-03 |
| Phase | NA |
What the finished NCT02366156 record still lists
NCT02366156 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02366156 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02366156 about?
NCT02366156 is a clinical study titled "A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism". This study will evaluate the effects of encapsulated botanical extracts, previously shown to inhibit the enzyme diacylglycerol-acyltransferase-1 (DGAT-1) in vitro, on fasting and postprandial lipid metabolism during an oral fat tolerance test (OFTT) in apparently healthy, overweight and obese adult ...
What is the current status of trial NCT02366156?
This trial is currently completed. It is a NA study. The enrollment target is 93 participants. The study started on 2014-07. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02366156?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Low Dose Grape Blend (DIETARY_SUPPLEMENT), High Dose Grape Blend (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02366156?
This trial is sponsored by Access Business Group, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02366156's enrollment target sits among peer trials
93 937th of 2000 higher than 1,064 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia